These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9761094)

  • 1. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty.
    Garbarz E; Farah B; Vuillemenot A; André F; Angioï M; Machecourt J; Bassand JP; Wolf JE; Danchin N; Prendergast B; Iung B; Vahanian A
    Am J Cardiol; 1998 Sep; 82(6):800-3, A9. PubMed ID: 9761094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty.
    Muhlestein JB; Karagounis LA; Treehan S; Anderson JL
    J Am Coll Cardiol; 1997 Dec; 30(7):1729-34. PubMed ID: 9385900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of abciximab in the prevention of the acute thrombotic complications of coronary angioplasty].
    Mesquita A; Baptista J; Almeida M; Ferreira J; Machado F; Palos L; Silva A; Seabra-Gomes R
    Rev Port Cardiol; 1997 Dec; 16(12):1031-5. PubMed ID: 9522626
    [No Abstract]   [Full Text] [Related]  

  • 4. Double vessel occlusions after balloon angioplasty treated by stenting and subsequently by abciximab infusion.
    Bertrand OF; Meerkin D; de Guise P; Crépeau J; Bourassa MG
    Can J Cardiol; 2000 Jan; 16(1):83-5. PubMed ID: 10653937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty.
    Fuchs S; Kornowski R; Mehran R; Gruberg L; Satler LF; Pichard AD; Kent KM; Stone GW; Leon MB
    J Invasive Cardiol; 2000 Oct; 12(10):497-501. PubMed ID: 11022207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
    van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
    Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
    Stone GW
    Am J Cardiol; 1999 May; 83(9A):16E-20E. PubMed ID: 10357577
    [No Abstract]   [Full Text] [Related]  

  • 9. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.
    Ellis SG; Lincoff AM; Miller D; Tcheng JE; Kleiman NS; Kereiakes D; Califf R; Topol EJ
    J Am Coll Cardiol; 1998 Nov; 32(6):1619-23. PubMed ID: 9822087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
    Lefkovits J; Ivanhoe RJ; Califf RM; Bergelson BA; Anderson KM; Stoner GL; Weisman HF; Topol EJ
    Am J Cardiol; 1996 May; 77(12):1045-51. PubMed ID: 8644655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock.
    Giri S; Mitchel J; Azar RR; Kiernan FJ; Fram DB; McKay RG; Mennett R; Clive J; Hirst JA
    Am J Cardiol; 2002 Jan; 89(2):126-31. PubMed ID: 11792329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of abciximab for treatment of early coronary artery stent thrombosis.
    Casserly IP; Hasdai D; Berger PB; Holmes DR; Schwartz RS; Bell MR
    Am J Cardiol; 1998 Oct; 82(8):981-5. PubMed ID: 9794358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study.
    Wong A; Mak KH; Chan C; Koh TH; Lau KW; Lim TT; Lim ST; Wong P; Sim LL; Lim YT; Tan HC; Lim YL
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):445-52. PubMed ID: 15274152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Instant dissolution of intracoronary thrombus by abciximab.
    Lee CH; Ho KT; Tan HC
    Int J Cardiol; 2005 Sep; 104(1):102-3. PubMed ID: 16137518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from late-breaking clinical trials sessions at ACCIS '99 and ACC '99. American College of Cardiology.
    Morris DC
    J Am Coll Cardiol; 1999 Jul; 34(1):1-8. PubMed ID: 10399983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.